Comprehensive Assessment of Cancer Theranostic Response

Study acronym: TRAQinform
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 6 more changesShow less
    • Final enrollment: 25 participants (planned 32)
    • Primary completion date changed from estimate of Mar 30, 2026 to Aug 31, 2026
    • Study completion pushed from May 29, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 2 of 2 sites
  2. Phase: Not specified to Not applicable
    • Primary completion date: Aug 31, 2025 to Mar 30, 2026
    • Study completion date: Feb 26, 2026 to May 29, 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.
Trial Details
NCT Number NCT06815354
Lead Sponsor AIQ Solutions
Collaborators: National Cancer Institute (NCI), Weill Medical College of Cornell University, M.D. Anderson Cancer Center
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov